Pipeline

In the table below, please find links to additional information on each pipeline program:

Product Candidate	Mode of Action	Indication	Commercial Partner
Lixisenatide (Lyxumia®)	GLP-1 agonist	Type 2 diabetes	Sanofi
Lixisenatide and Lantus^® pen combination	GLP-1 agonist and insulin	Type 2 diabetes	Sanofi
ZP2929	GLP-1 agonist/Glucagon agonist	Type 2 diabetes and obesity	Boehringer Ingelheim
Elsiglutide	GLP-2 agonist	Chemotherapy-induced diarrhea	Helsinn Healthcare
ZP1848	GLP-2 agonist	Inflammatory Bowel Disease	Zealand Pharma
Danegaptide	Gap junction modifier	Atrial Fibrillation	Zealand Pharma
ZP1480	Melanocortin receptor agonist	Post-surgical Acute Kidney Injury (AKI)	Action Pharma

Tip a friend

Fill in the form below to tip a friend about this page.

When this page is updated you will be updated by e-mail.